BackRegulus Therapeutics Overview

Regulus Therapeutics EBIT

EBIT (Earnings Before Interest and Taxes) analysis for RGLS.

Quarterly EBIT

-$10.54M
↓ 18.31% YoY

As of Mar 31, 2025

Annual EBIT (TTM)

-$50.79M
↓ 57.56% YoY

Trailing 12 months ending Mar 31, 2025

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin